U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT07570082) titled 'Drug-Drug Interaction Study of Atumelnant in Healthy Participants' on April 29.
Brief Summary: This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
Study Start Date: May 06
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: Atumelnant
Atumelnant, tablets
DRUG: Carbamazepine
CYP3A4 inducer
DRUG: Midazolam
CYP3A4 substrate
DRUG: Digoxin
P-gp substrate
DRUG: Metformin
MATE1/2-K substrate
Recruitment Status: RECRUITING
Sponsor: Crinetics P...